Is there a preferred diuretic class for patients with renal impairment and hypertension?

Journal of the American Society of Hypertension

Volumn 10, Issue 4, 2016, Pages 282-284

  Izzo, Joseph L ^a,b   Tobe, Sheldon W ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chronic kidney disease; hypertension; loop diuretics; thiazide diuretics

Indexed keywords

AMILORIDE; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BUMETANIDE; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE; EPLERENONE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS SPIRONOLACTONE; LOOP DIURETIC AGENT; METOLAZONE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; SODIUM;

CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; DIURESIS; HUMAN; HYPERTENSION; HYPERVOLEMIA; KIDNEY FUNCTION; NATRIURESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; COMBINATION DRUG THERAPY; COMPLICATION; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; URINE;

ANTIHYPERTENSIVE AGENTS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; SODIUM; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; THIAZIDES; TREATMENT OUTCOME;

EID: 84960145165     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2016.02.008     Document Type: Note

References (8)

1. G. Eknoyan A history of edema and its management Kidney Int Suppl 59 1997 S118 S126
2. P. Pickkers, A.D. Hughes, F.G. Russel, T. Thien, and P. Smits Thiazide-induced vasodilation in humans is mediated by potassium channel activation Hypertension 32 1998 1071 1076
3. R.D. Feldman, Y. Hussain, L.M. Kuyper, F.A. McAlister, R.S. Padwal, and S.W. Tobe Intraclass differences among antihypertensive drugs Annu Rev Pharmacol Toxicol 55 2015 333 352
4. M. Epstein, and D.A. Calhoun Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics J Clin Hypertens 13 2011 644 648
5. M.J. Brown, C.R. Palmer, A. Castaigne, P.W. de Leeuw, G. Mancia, T. Rosenthal, and et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) [Erratum appears in Lancet 2000 Aug 5;356(9228):514] Lancet 356 2000 366 372
6. B. Williams, T.M. MacDonald, S. Morant, D.J. Webb, P. Sever, G. McInnes, et al. British Hypertension Society's PSG Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial Lancet 386 2015 2059 2068
7. B. Pitt The role of mineralocorticoid receptor antagonists in patients with American College of Cardiology/American Heart Association stage B heart failure Heart Failure Clin 8 2012 247 253
8. J.L. Izzo Value of combined thiazide-loop diuretic therapy in chronic kidney disease: heart failure and renin-angiotensin-aldosterone blockade J Clin Hypertens 14 2012 344